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Abstract: ABCB1 modulation is an interesting strategy in search for 
new anticancer agents overcoming multidrug resistance (MDR). 
Hence,  17 new 5-arylideneimidazolones containing amine moiety, as 
potential ABCB1 inhibitors was designed, synthesized, and 
investigated. The series was tested in both, parental (PAR) and 
multidrug resistant (MDR) overproducing ABCB1, T-lymphoma 
cancer cells using cytotoxicity assay. The ABCB1 modulating activity 
was examined in the rhodamine 123 accumulation test, followed by 
Pgp‐Glo™ Assay to determine an influence of most active compounds 
on ATPase. Lipophilic properties were assessed both, in silico and 
experimentally (RP-TLC). Pharmacophore-based molecular 
modelling towards ABCB1 modulation was performed. The studies 
allowed to find anticancer agents (p-fluorobenzylidene derivatives) 
more potent than doxorubicin, with highly selective action on MDR T-
lymphoma cells (selectivity index > 40). Most of the investigated 
compounds showed ABCB1-modulating action, especially, two 5-
benzyloxybenzylidene derivatives displayed activity nearly as strong 
as tariquidar. 
Introduction 
Multidrug resistance (MDR) is the significant problem in the 
treatment of cancer [1]. For most patients, who suffer from 
metastatic cancer, treatment fails because of MDR [1,2]. Due to 
this substantial situation, a search for new therapeutic solutions 
to overcome cancer MDR is of great importance for current 
medicinal science. One of proposed approaches are “adjuvants” 
for anticancer drugs, which are able to block at least one of the 
mechanisms of MDR. In this context, many studies have been 
carried out in order to find compounds capable to modulate 
transport proteins representing one of the main mechanisms of 
MDR in cancer cells [1,3,4]. Among them, the efflux pumps that 
belong to ATPase binding cassette (ABC) family are of great 
scientific interest [1]. In particular, ABCB1 transporter, often 
named glycoprotein P (Pgp), is widely described target that has 
complex structure with many drug-binding domains, and 
consequently, wide variety of substrates [1]. Various assays have 
indicated significant role of this efflux pump in cancer MDR due to 
the potency to expel many, structurally unrelated, anti-cancer 
drugs. Furthermore, the overexpression of this pump in clinical 
MDR cancer cells has been confirmed [1,5,6]. Thus, searching for 
ABCB1 modulators has been a topic of cancer medicinal 
chemistry for decades. As results, various active structures, which 
can be divided into four generations, have been found. 
Compounds, which belong to the first and second generations of 
ABCB1 modulators, were found among known drugs, e.g. 
verapamil or cyclosporine A [7]. However, these generations 
indicate action on other targets, usually more potent than that on 
ABCB1, which limits their application as “adjuvants” in cancer 
treatment [1,7]. The third generation of ABCB1 inhibitors, e.g. 
tariquidar or zosuquidar, were significantly more potent than 
previous generations [6]. Unfortunately, these compounds are not 
enough safe for therapeutic usage due to various toxic effects 
[3,6]. One of the explanations is their toxicity to healthy human 
cells due to the presence of ABCB1 efflux pump in both, normal 
and tumor cells [1,3]. Dash et al. pointed out ADME properties as 
a main drawback of those compounds [8]. Nowadays, there are 
studies conducted with natural products e.g. chalcones, flavonols, 
flavones, which were assigned as the fourth generation [9-11]. 
Despite higher safety of the new compounds, various 
disadvantages associated with them have been reported. 
Currently, there are studies focused on synthetic modifications of 
natural products in order to boost pharmacokinetic parameters 
[10-13]. 
At the continuous absence of ABCB1-targeted “adjuvants” in 
pharmaceutical market, and taking into account their potential 
advantages for the cancer therapy development, the search for 
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science, involving various approaches of medicinal chemistry. 
Thus, Cianchetta et al. pointed out that pharmacophore model 
rather than physicochemical properties prediction allowed for 
recognition of ABCB1 substrates among series of designed 
chemical compounds [14]. They presented one model for all 
substrates, which showed some similarities to other 
pharmacophore models [14-16]. However, various studies have 
indicated differences between pharmacophore features, 
depending on structure of the compounds that were used for their 
hypotheses [14,17]. For instance, the pharmacophore postulated 
by Reyes et al. does not possess basic tertiary amine, which was 
presented in other models [17,18]. Due to that, it seems, that 
pharmacophore models should be created separately for each 
chemically-related group of designed and tested ABCB1 
modulators. 
On the other hand, physicochemical properties seem to play 
crucial role in the ABCB1 modulating potency. Various lines of 
evidence pointed out shape and size as important feature [14,19], 
while lipophilicity is the most frequently considered property. 
Hence, Cianchetta et al. [14] indicated a weak correlation of logP 
in their model, whereas Wiese and Pajeva [18] emphasized high 
lipophilicity as desirable feature of ABCB1 modulators. Moreover, 
Jain et al., based on their work on sipholane triterpenoids (1, 
Figure 1) [20], accented that strong ABCB1 modulators should 
possess logP higher than 2.92. In contrast, poor correlation was 
indicated between activity and logP for chalcone derivatives (2, 
Figure 1) [21]. Although the aforementioned results does not 
provide coherent information about the role of lipophilicity for 
ABCB1 modulators, they indicate that the assessment of this 
property should be an integral part of initial search for ABCB1 
modulators in any new chemical family. 
Taking into account both, the need to find effective and 
pharmacologically safe ABCB1 modulators that finally would get 
pharmaceutical market and the growing interest of modern 
medicinal chemistry in multi-target drugs, it is especially 
promising to search for new anticancer agents, selective towards 
MDR cancer cells, with simultaneous MDR-reversal properties.  
 
 
Figure 1. Examples of potential ABCB1 modulators from the group of sipholane 
triterpenoids (1) and chalcones (2) [20,21]. 
Our previous studies indicated that some of imidazolone and 
hydantoin derivatives were able to modulate the efflux pump 
ABCB1 [22-24]. The specific activity in the ethidium bromide 
assay was found for the amine-free hydantoins with 
benzyloxybenzylidene moiety at position 5 (3, Figure 2) [23]. In 
particular, imidazolones with an amine group at position 2 or 2 
and 3, demonstrated the potential ABCB1 modulating activity (4 
and 5, Figure 2) stronger than verapamil [24]. Previous studies 
have provided useful conclusions coming from performed SAR 
analysis. Thus, the following traits for imidazolones able to 
modulate ABCB1 have been postulated: (i) the aromatic moiety; 
(ii) the positive ionizable center; (iii) the hydrophilic moiety, (iv) the 
alkyl linker and (v) the hydrogen bond acceptor [22]. However, the 
anticancer cytotoxicity of those series was usually negligible or 
moderate in the best case [22-24]. 
Although our previous search for the imidazolone-derived ABCB1 
modulators was comprehensive, two important aspects have 
been missed so far, i.e. a comparison of the activities between 
those compounds and strong inhibitors of third generation as well 
as a pharmacophore model for 5-arylideneimidazolones. Above 
all, previous pharmacomodulation in the imidazolone group was 
focused on a single ABCB1-modulating action, and their anti-
tumor effects did not clearly differentiate between MDR- and 
reference cancer cells (selectivity index, SI < 1) [24]. 
For the aforementioned reasons, searching for more potent 
ABCB1-modulators, with MDR-selective anticancer action among 
further imidazolone derivatives was needed. In this context, a 
general structure for new imidazolones (6, Figure 2) as 
combination of fragments coming from previously found active 
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Within this study, a series of 17 new 5-arylideneimidazolone 
derivatives (7-23), covering the general structure 6, was 
designed, synthesized and investigated. The series was 
divided into two groups depending on position of the amine 
moiety, i.e. the group A (7-13, Table 1) with the amine fragment 
only in position 2 of the imidazolone ring and the group B with 
amines at both, 2 and 3, positions (14-23, Table 2). The 
compounds were examined on their cancer cell cytotoxic 
effects, followed by an assessment of ABCB1 efflux pump 
modulating properties using in vitro assays. The ATPase 
substrate property for selected compounds was determined. 
Based on the obtained results, molecular modelling, in order to 
elaborate new pharmacophore hypothesis useful for 
imidazolone ABCB1 modulators, was performed. In term to 
verify an influence of physicochemical properties on the 
considered biological actions, the lipophilicity tests using both, 
experimental and in silico, methods were conducted for the 
whole series (7-23). Finally, SAR analysis was performed and 
discussed. 
Table 1. Structures of the investigated compounds from group A (7-13). 
 
 






















































Table 2. Structures of the investigated compounds from group B (14-23). 
 
 














































Results and Discussion 
Chemical synthesis 
 
Final products (7-23) were obtained in the 3-5-step synthetic 
pathways (Scheme 1). Methods of synthesis for intermediates 
30, 31, 36, 38, 39, 44 and the final product 7 were described 
previously [25,26]. First (Scheme 1a), two-step Gabriel 
synthesis was performed, i.e.: (i) the N-alkylation of 
phenylpiperazine with the bromopropyl phthalimide to give 
intermediate 24, followed by (ii) hydrazinolysis of 24 to obtain 
the primary amine derivative of phenylpiperazine (25), useful 
as an intermediate for further synthesis. As the next group of 
intermediates, the 3-benzyloxybenzaldehydes (26-29) were 
obtained via O-alkylation of 3-hydroxybenzaldehyde with 
appropriate benzyl chlorides or bromide using two-phase 
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condensation of aldehydes (26-29 or the commercially 
available ones) with 2-thiohydantoin was carried out (i, 
Scheme 1c), which gave the 5-arylideneimidazolones (30-37) 
in Z-configuration, preferable for this kind of syntheses 
according to previous crystallographic studies [25, 26] . In the 
next step (ii, Scheme 1c), the intermediates 30-37 were S-
methylated with iodomethane to give the S-metyl-5-
arylideneimidazolones (38-45). In the last step, reactions 
between intermediates (38-45) and proper amines (iii, Scheme 
1c) gave the final products 7-23. In case of the reactions with 
primary amines, Dimroth rearrangement (iv, Scheme 1c) for 
compounds 14-23 was assumed, based on previous 
crystallographic studies and NMR results [25]. General 
mechanism of Dimroth rearrangement in this group was 
previously published [25], while example from current studies 
is provided in Supporting Information (Scheme S1). Products 
7-23 were converted into hydrochloride salts by saturation of 
their post-reaction mixture with gaseous HCl.
 
Scheme 1. Synthesis of compounds 7-45. a) Synthesis of 3-(4-phenylpiperazin-1-yl)propan-1-amine: (i) 1-phenylpiperazine, K2CO3, TEBA, acetone, reflux, 5 h, rt, 
72 h; (ii) hydrazine, ethanol anhydrous, reflux, 6 h, rt, 72 h. b) Synthesis of the 3-benzyloxybenzaldehyde derivatives (26-29): (un)substituted benzyl halide, K2CO3, 
ethanol, reflux, 6 h. c) Synthesis of final compounds 7-23: (i) appropriate aromatic aldehyde, CH3COONa, CH3COOH, reflux, 5-7 h; (ii) CH3I, C2H5ONa, rt, 24 h; (iii) 
appropriate amine, 125°C, 15 min, ethanol, reflux, 5-7 h, rt, 20 h, saturation with gaseous HCl; (iv) Dimroth rearrangement, saturation with gaseous HCl. * Dimroth 
rearrangement was confirmed by crystallographic studies for products of reactions between S-methyl imidazolones and the primary amines terminated and has 
been assumed  for  compounds  14-23 based on the structural analogy and NMR results. 
Cytotoxicity assays 
 
Prior to estimate an impact on ABCB1 for synthesized 2-
amine-5-arylideneimidazolones (7-23), their cytotoxicity was 
examined using MTT assays [27]. The assays were performed 
in two mouse T-lymphoma cell lines: the chemosensitive 
parental (PAR) and the multidrug resistant (MDR) ones. The 
MDR subline was acquired through transfection with human 
MDR1 (ABCB1) gene. The cytotoxic effects were expressed 
with IC50 values. The IC50 values for PAR cells were divided by 
those for MDR cells to calculate selectivity index (SI, Table 3). 
Almost all of tested compounds (7-23) had moderate 
cytotoxicity (IC50 > 20 μM) in PAR cells. Only compound 23 
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Furthermore, this compound displayed even stronger activity 
(IC50 = 8.80 μM) in the case of MDR cells. 
The most potent action in MDR cells was observed for 
compounds 14 and 15 with IC50 equal to 2.37 or 2.15 μM, 
respectively. Interestingly, these compounds were not 
cytotoxic towards PAR cells (IC50 > 100 μM), thus 
demonstrating highly selective action (SI > 40). In order to 
compare the selectivity of the series (7-23), the SI = 1.5 was 
established as a breaking point. Hence, SI >1.5 was 
considered as an indicator of a selective anticancer agent. 
Based on this classification, compounds 9, 12, 14, 15 and 23 
were selective derivatives with a SI of > 2.9, 1.87, > 42.19, > 
46.51, and 1.69, respectively. 
Table 3. Cytotoxicity of 5-arylideneimidazolones (7-23) in PAR and MDR 
mouse T-lymphoma cell lines. 
PAR, parental T‐lymphoma cells; MDR, multidrug‐resistant T‐lymphoma 
cells overproducing efflux pump ABCB1; SD, standard deviation calculated 
from four repetitions; SI, selectivity index; DOX, doxorubicin; starting 
concentration of tested compounds in the MTT assay: 100 μM. The best 
cytotoxicity and selectivity results underlined. 
 
Rhodamine 123 accumulation assay 
 
An ability of the 2-amine-5-arylideneimidazolones (7-23) to 
affect ABCB1 efflux pump was tested using rhodamine 123 
accumulation assay. It was determined in both afore-
mentioned, PAR and MDR, mouse T-lymphoma cell lines. 
Results of this assay were obtained using flow cytometry. This 
method measures the intracellular accumulation of rhodamine 
123, which is a fluorescent substrate of the ABCB1 efflux pump. 
The data obtained were calculated and presented as a 
measure of efflux pump modulatory properties, named the 
fluorescence activity ratio (FAR). Tariquidar, the highly potent 
representative of third generation ABCB1 inhibitors, was 
chosen as reference. The tested compounds (7-23) were 
divided into two separate experiments, which caused elicitation 
of various tariquidar FAR. Due to that, results were also 
expressed using FAR quotient (% of tariquidar FAR) to enable 
comparison of the action in the whole series with respect to 
that of tariquidar, but used in the significantly lower 
concentration. 
Nine out of seventeen tested 5-arylideneimidazolones (9, 10, 
12, 13, 19-23) showed activity of ABCB1 modulators (FAR = 
3.095 - 30.860) at 20 μM concentration (Table 4). Compound 
20 demonstrated a moderate activity (FAR = 11.331), while two 
others (12 and 22) displayed strong activity with FAR values 
28.269 and 30.860, respectively. These two compounds (12, 
22) were nearly as effective as tariquidar (FAR quotient = 
87.591 % or 95.620 %, respectively). 
Table 4. Results of rhodamine 123 accumulation assay for 2-amine-5-
arylideneimidazolones (7-23) tested in MDR mouse T-lymphoma cell lines. 
Results of Rhodamine 123 Accumulation 
Cpd 







7 1 1.105 3.423 1.972 6.109 
8 1 1.225 3.796 1.783 5.526 
9 1 2.031 6.292 4.452 13.796 
10 2 1.617 4.325 3.214 8.599 
11 2 2.090 5.592 1.462 3.911 
12 1 15.147 46.934 28.269 87.591 
13 2 1.952 5.223 5.976 15.987 
14 2 1.148 3.070 1.029 2.752 
15 2 1.536 4.108 1.276 3.414 
16 2 0.490 1.312 0.593 1.586 
17 2 0.357 0.955 0.495 1.325 
18 2 0.383 1.025 0.662 1.771 
19 1 1.362 4.219 3.910 12.117 
20 1 2.224 6.891 11.331 35.109 
21 2 1.521 4.070 3.095 8.280 
22 1 15.807 48.978 30.860 95.620 
23 1 2.120 6.569 6.360 19.708 





0.678 1/ 0.233 
2 (V/V%) 
2.102 1/ 0.624 2 - - 
Cpd, compound; TAR*, Tariquidar, tested in 0.2 μM concentration; DMSO, 
dimethyl sulfoxide; FAR, fluorescence activity ratio; FAR Quotient: 
compounds` FAR related to FAR of 0.2 μM TAR; 1,2 Compounds were tested 
in two groups with respect to different FAR values for TAR and DMSO. The 
two highest FAR and FAR quotients underlined. 
Studies in vitro on ABCB1 modulation mechanisms 
 
The most active 5-arylideneimidazolones in rhodamine 123 
accumulation assay (12, 20, and 22) were chosen for the 
determination of potential molecular mechanisms of action in 
the assay in vitro. Thus, the luminescence Pgp‐Glo™ Assay 
was carried out based on already described methods and 
protocols [24, 28-30]. This assay analyzes consumption of 
Cpd 
Mouse T-lymphoma cell line 
PAR MDR 
SI 
IC50 (μM) SD ± IC50 (μM) SD ± 
7 79.72 3.02 > 100 - ≤ 0.80 
8 > 100 - 70.54 0.056 > 1.42 
9 > 100 - 34.48 0.4 > 2.90 
10 45.42 3.36 40.19 2.77 1.13 
11 44.45 1.46 50.39 0.93 0.88 
12 33.20 0.89 17.77 1.02 1.87 
13 >100 - >100 - > 1.00 
14 >100 - 2.37 0.11 > 42.19 
15 >100 - 2.15 0.03 > 46.51 
16 32.11 1.83 31.38 2.6 1.02 
17 97.57 0.29 97.90 0.45 1.00 
18 46.56 1.39 41.93 0.77 1.11 
19 22.02 0.95 20.7 0.39 1.06 
20 30.50 4.04 24.53 0.33 1.24 
21 26.96 1.49 35.92 1.79 0.75 
22 34.53 0.29 32.85 0.78 1.05 
23 14.89 0.47 8.80 0.67 1.69 
DOX 0.37 0.03 3.5 0.1  
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energy, necessary for efflux, which is obtained from ATP 
hydrolysis. The consumption of ATP is observed as decrease 
in luminescence. Basal activity, which demonstrates the 
ABCB1 basal ATP consumption, is considered as a difference 
between the luminescent signal of two samples: (i) treated with 
the selective and strong (100 %) ABCB1 inhibitor, Na3VO4, and 
(ii) the luminescence of untreated ABCB1 samples. Hence, 
stimulators/substrates cause a statistically significant increase 
in the basal activity, while inhibitors give results below 100 % 
of the basal activity.  
Compounds 12, 20, and 22 were tested in 100 μM 
concentration. Verapamil as reference, which possesses the 
substrate/ATPase stimulatory mode of action, at 200 μM was 
used. As a negative control, caffeine (inactive toward the 
ABCB1 transporter) was selected. Results are shown in Figure 
3.  
 
 Figure 3. The effect of various compounds on ABCB1 basal activity as 
follows: VER, verapamil, the ABCB1 substrate (200 μM); CFN, caffeine, 
ABCB1‐negative compound (100 μM); and 5-arylideneimidazolone 
derivatives 12, 20, and 22 (100 μM). ABCB1 substrates give results above 
100% due to stimulation of basal activity. Results are presented as the mean 
± SD from 3 repetitions. One‐way ANOVA was used for evaluation of 
statistical significance, and was followed by Bonferroni’s comparison test (** 
p < 0.01, *** p < 0.001, **** p < 0.0001 compared to the basal activity). 
All tested compounds (12, 20, and 22) caused the statistically 
significant (p < 0.001 or p < 0.0001) increase in basal activity, 
higher than that of verapamil. Thus, none of the three 
compounds displayed properties of ATPase inhibitor but, in 
similarity to verapamil, they can be considered substrates 
stimulating ATPase with different potency. The higher potency 
was observed for compounds representing group B (20 and 
22), while the member of group A (12) was less active and only 
slightly more potent than verapamil. 
In this context, the mechanism of ABCB1 modulation observed 
in the rhodamine 123 accumulation assay for compounds 12, 
20, and 22 (Table 4) was not associated with the pump 
inactivation via ATPase inhibition. These results are in 
compilations with previous ones obtained for imidazolones and 
hydantoins [24, 27]. It suggests a competition with the dye-
substrate towards ABCB1 binding site as the most probable 
mechanism of the pump modulating action for compounds 12, 
20 and 22.  
 
Pharmacophore model of ABCB1 modulator 
 
Pharmacophore modelling was used in order to highlight the 
common structural features of the compounds with significant 
capacity to inhibit the MDR-efflux pump. The set of actives 
used to develop appropriate hypotheses consisted of 
compounds 12, 20, 22, and lead structures 4 and 5, whereas 
set of inactives included compounds 7-11, 13-19, 21, and 23 
(Figure 2, Table 1 and 2) [24]. The resulted pharmacophore 
model was developed using Phase (Schrödinger Software) 
[31] and postulated five structural features, i.e.: two aromatic 
rings (AR1 and AR2), hydrogen bond donor (HBD), protonable 
nitrogen atom (PI) and hydrogen bond acceptor (HBA, Figure 
4A). All the distances between the particular structural features 
are presented separately in Table 5, in order to maintain the 
clarity of Figure 4A. Overlapping the structures of highly active 
compound 22 (Figure 4B) and inactive compound 14 (Figure 
4C) into the hypothesis showed the necessity of presence of 
two aromatic rings instead of one ring.
 
Figure 4. (A) The proposed pharmacophore hypothesis for MDR-reversing activity among 5-arylideneimidazolones (AR – aromatic ring; HBD – hydrogen bond 
donor; PI – protonable nitrogen atom; HBA – hydrogen bond acceptor; grey sphere – tolerance area ±2Å); (B) the example of highly active compound 22 mapped 
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Lipophilicity is consider as important parameter for ABCB1 
inhibitors. Therefore, an estimation of this parameter using 
both, experimental and in silico methods was conducted for the 
whole investigated series (7-23). Firstly, lipophilic properties 
were determined experimentally, followed by in silico prediction 
for the basic forms of compounds 7-23 with the use of four 
computer programs.  
 
Lipophilicity estimation using RP-TLC method  
Lipophilicity was determined experimentally using standard 
RP-TLC method. Results are presented as RM0 values (Figure 
5) reflecting lipophilic properties on the basis of retention 
parameters, which are presented with details in Supporting 






Figure 5. Lipophilicity (RM0) of tested 2-amine-5-arylideneimidazolones (7-23) determined experimentally using RP-TLC method. 
The 2-amine-5-arylideneimidazolones (7-23) displayed RM0 
values between 1.48 and 3.35. Lipophilicity in both groups (A 
and B) was variable and no significant advantage was found 
for any group. Group B (14-23) consists of compounds with 
both, minimal (16) and maximal (21), values. In the case of 
group A (7-13), results for compounds with two fused rings (7 
and 8) were quite similar to each other (2.60 and 2.75, 
respectively). The opposite situation could be seen for the 
unfused ring compounds (RM0 = 1.83-2.99). Interestingly, 
compound 13, with the phenanthrene moiety at position 5, 
demonstrated rather low lipophilicity (RM0 = 1.83) in comparison 
to other representatives. An analysis of the results for 
imidazolones from group B with the same aromatic moiety, 
indicates that compounds with N-methylpiperazine fragment 
were more lipophilic than those with the corresponding 
morpholine moiety (15 vs 14, 19 vs 18, 21 vs 20 and 23 vs 22). 
Moreover, changing from propyl (18) to ethyl (17) linkers 
increased RM0 value from 2.21 to 2.56. Interestingly, the 
highest results in both groups (2.99 and 3.35) were obtained 
for the 3-((4-fluoro)benzyloxy)benzylidene derivatives (10 and 
21, respectively). 
The lack of regular relationship between chemical structure 
and lipophilicity can be explained by extended polymorphism 
of compounds 7-23 proved by elemental analysis. The 
chemical characteristics (see Experimental, Chemical 
synthesis) indicate that these compounds form different 
crystallographic sequences, from mono- to trihydrochloric salts, 
simultaneously being hydrates (in content 0.5-3.5 of H2O per 
molecule), excluding compound 16. The interference of two 
opposing traits, i.e. the hydrophilicity-increasing hydrochloride 
form on one hand, and the hydrate-form strongly reducing 
hydrophilicity on the other, together with the lipophilicity 
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resulting from a single molecule structure, seems to cause the 
irregular difference of the RM0 measured (Figure 5). The lowest 
lipophilicity observed for the only non-hydrate compound 16, 
obtained in the triple-hydrochloride form, distinctly supports 
this theory. However, the resultant of the triple overlapping 
effects is not so easy to find for other members of the series 
(7-15, 17-23).   
 
Lipophilicity prediction in silico  
In order to verify the role of polymorphism in matting the 
lipophilic properties of single molecule in the interaction with 
the ABCB1 pump at the molecular level, logP was calculated 
for the compounds (7-23) in the basic forms. Thus, in silico 
assays were performed with the use of four bioinformatics tools, 
i.e. SwissADME [32], pkCSM [33], molinspiration [34], and 
ALOGPS [35, 36]. Results, including mean value of logP and 
standard deviations from all used programs, are shown in 
Figure 6, while detailed data are presented in Supporting 
Information (Table S2). 
Figure 6. Results of lipophilicity from in silico prediction calculated for 5-arylideneimidazolones (7-23) in basic forms, presented as arithmetic mean from all obtained 
values with standard deviations. 
The lowest mean values of logP were obtained by compounds 
with single aromatic ring at position 5 of imidazolone and only 
aliphatic moieties at other positions (14 and 15). For 
benzyloxybenzylidene derivatives from both groups A (9-12) 
and B (17-23), an increase of lipophilicity due to addition of 
halogen is clearly visible. Furthermore, compound 12 
containing two chlorine atoms acquired the highest lipophilicity 
among all tested compounds. Compounds with amine only at 
position 2 demonstrated higher logP than those with amine at 
positions 2 and 3 (9 vs 17, 18, and 19; 10 vs 20, 21; 11 vs 22, 
23; Group A vs B).  
In contrast to experimental results for salts (7-23), results 
simulated for the basic form of this series clearly demonstrate 
the larger aromatic moiety (including hydrophobic substituents), 
the higher logP value of the whole molecule. Moreover, it can 
confirm the remark from the experimental test (Figure 5) that 
compounds with N-methylpiperazine have usually slightly 




The series of new potential ABCB1 modulators (7-23) was 
rationally designed on the basis of previously found active 
imidazolone derivatives [23,24]. The new compounds possess 
various arylidene moieties at position 5, mostly 3-
benzyloxybenzylidene fragments. They were divided into two 
groups, depending on the position of amine fragments, i.e. the 
amine fragment connected to C2 of imidazolone ring in case of 
group A (7-13, Table 1), and the amine group at position 2- and 
the alkylamine group connected to position N3 of the 
imidazolone ring in the case of group B (14-23, Table 2). Such 
diversity of fragments at position 2, 3 and 5 of imidazolone ring 
together with comprehensive biological results give an 
opportunity to perform structure-activity relationship studies. 
Thus, the role of the following structural traits can be 
considered: (i) a type of aromatic moiety at position 5, (ii) the 
amine position (group A vs group B) and (iii) a kind of amine 
(N-methylpiperazine vs morpholine vs phenylpiperazine) 
connected to N3 with the alkyl chain in group B. 
In the cytotoxicity assays, three compounds (14, 15 and 23) 
displayed strong effect in MDR T-lymphoma cancer cells 
(Table 3). All of them belong to the group B. The 4-fluorophenyl 
(14, 15) seems to be the preferable aromatic moiety for the 
cytotoxic effect on MDR T-lymphoma cells, while the 
chlorobenzyloxybenzylidene compound 23 proved the 
nonselective cytotoxic action on both, MDR and PAR, cell lines. 
Referring to our previous research among imidazolones [24], 
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the single-ring aromatic moiety- or phenoxybenzylidene-
containing compounds. An introduction of these new moieties 
indisputably improved the desirable anticancer profile of the 
series of arylidene-imidazolones giving selectivity for MDR 
cancer cell line with respect to the parental ones. This 
relevance was not observed earlier [24]. Hence, five tested 
compounds, i.e. the benzyloxybenzylidene derivatives 9, 12, 
23, and the fluorobenzylidene ones (14, 15) could be 
considered selective anticancer agents (SI > 1.5; Table 3). The 
most selective compound 15 as well as compound 23 contain 
the N-methylpiperazine fragment, whereas the remained three 
ones (9, 12, and 14) are morpholine derivatives. Results for the 
fluorobenzylidene derivatives 14-16 allow to evaluate the role 
of the amine termination at position 3. Thus,  non-aromatic 
amines (14, 15), morpholine and N-methylpiperazine, seem to 
be preferable for the considered anticancer action comparing 
to the phenylpiperazine one (16). However, more 
fluorobenzylidene derivatives and more structural data are 
necessary in order to generalize this conclusion. 
Results for compounds 7-23 tested in rhodamine 123 
accumulation assay (Table 4) showed that the most active 
compounds (12 and 22) belonging to different groups (A and 
B, respectively), while one additional member of the group B 
(20) demonstrated moderate activity. Moreover, less active 
and inactive compounds can be found almost equally in both 
groups. Concerning amines in group B, the morpholine 
derivatives were usually more active ABCB1-modulators than 
N-methylpiperazine ones (20 vs 21 and 22 vs 23), and this 
observation is in a good agreement with our previous results 
[24]. However, for the 3-benzyloxybenzylidene moiety without 
substituents, the opposite result may be noticed. In the case of 
arylidene moieties, the final products with the 3-
benzyloxybenzylidene substitution were more potent ABCB1-
inhibitors than others investigated in this study, regardless of 
quantity of rings and the amine position. Furthermore, the 
addition of halogen to the phenyl ring seems to be beneficial. 
Interestingly, fluorine was preferable in the group A, while 
chlorine in group B, in the case of mono-substitution. 
An insight into the ABCB1-modulating mechanism for the most 
active compounds (12, 20, and 22) proved their potent activity 
as ATPase substrates (Figure 3). This, in accordance with 
previous results [24], suggests a competitive action with the 
fluorescent substrate (123 rhodamine) as the most probable 
mechanism of the efflux inhibition caused by this series. 
However, the obtained ATPase-stimulation results for the 2,3-
disubstituted compounds (20, 22) were significantly higher 
than that of reference verapamil and most of the previous 
imidazolones tested [24].  
The structure-activity relationship analysis for this series (7-23) 
gives three important conclusions concerning three 
compounds presented within this study. First, the 
benzyloxybenzylidene compound 12 (group A) seems to be 
particularly interesting due to the MDR-cancer selectivity (SI: 
1.87) and the potent ABCB1 modulating properties (the 
significant FAR at 2 M, Table 4). Secondly, the 
fluorobenzylidene derivatives 14 and 15 have been found as 
very promising anticancer agents, even more potent than 
doxorubicin. Thirdly, their action was highly selective towards 
MDR cancer cell line (SI > 40) but, interestingly, both 14 and 
15 did not influence ABCB1 efflux pump in the rhodamine 123 
accumulation assay. Worth to underline, the second and third 
conclusions are new attractive findings, which have not been 
noted in our previous studies [24].  
On the other hand, the pharmacophore model elaborated for 
5-arylideneimidazolones indicated five structural features 
(Figure 4A). Among them, two aromatic rings are the features 
in concordance with previously obtained results. Interestingly, 
the presence of chlorine in the most active compounds (12, 22) 
does not fit in to any feature of the pharmacophore model. 
Probably, this feature was not included in the pharmacophore 
hypotheses due to the absence of halogens within lead 
structures (4 and 5, Figure 2) also used to define the 
pharmacophore model. However, the halogen at the phenyl 
moiety additionally increases the general size and lipophilic 
properties of the hydrophobic aromatic area, which may be 
beneficial for appropriate interactions with ABCB1 protein. 
Thus, it should be considered in further design, that halogen, 
mainly chlorine, could increase activity. This pharmacophore 
model also indicates three other features, i.e. hydrogen bond 
acceptor (HBA), hydrogen bond donor (HBD) and protonable 
nitrogen atom (PI). This points out an impact of the amine 
fragment spaced from imidazolone ring.  
In the biological research performed, representatives of both 
groups, A and B, demonstrated the desirable activity. These 
groups did not show any regular relationship between lipophilic 
properties evaluated experimentally and their biological 
activities (Figure 5). It is only seen that group B demonstrated 
wider range of RM0 values. In general, compounds with N-
methylpiperazine were more lipophilic than morpholine, if they 
contained two unfused rings at position 5 of the imidazolone 
ring. The opposite results, however, were observed for the 
fluorophenyl derivatives. In contrast to the previous studies 
concerning hydantoin derivatives [27], the resultant lipophilicity 
of compounds did not affect the ABCB1 modulating potency in 
this series (7-23). As the clearest example, the most lipophilic 
compound 21 did not demonstrate ABCB1-modulating action, 
while the most active modulator 22 showed in 1-unit lower 
lipophilicity than that of 21 (2.30 vs 3.35, Figure 5). However, 
the comparison of experimental lipophilic properties was not 
easy within this series due to the polymorphic variety, i.e. the 
different HCl salt-hydrate balance for particular compounds. 
Otherwise, the in silico simulation of lipophilic properties for the 
basic form of each member of the series (7-23) gave some 
support for these considerations. Thus, it can be seen that 
compounds with the lowest calculated logP (14 and 15) 
demonstrated the most potent cancer cytotoxicity in MDR cell 
line and significant selectivity index. However this deduction is 
not followed by other compounds, e.g. the compound 12 with 
SI > 1.5 acquired the highest calculated logP. In the case of 
relationship between logP and ABCB1 inhibiting properties, 
some pattern can be observed (Figure 6 vs Table 4). 
Compounds with the top FAR obtained either the highest (12,  
group A) or one of the highest (22, group B) results of the 
calculated logP. Compounds with the lowest logP  (7 and 8, 
Group A; and 14, 15, 17, and 18 from Group B) were also 
deprived of the ABCB1 modulating properties.  
On the basis of the SAR analysis performed, the (i) 4-
fluorophenyl moieties, which contain (ii) N-methylpiperazine or 
morpholine, placed in the topological mode of group B, 
occurred beneficial in search for selective anticancer agents 
inhibiting growth of the resistant cancer cells. Such compounds 
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modifications in the search for new solutions to overcome 
cancer MDR. Furthermore, the compounds with (i) 
benzyloxybenzylidene substituent at position 5, which belong 
to (ii) either A or B topologic group and (iii) contain morpholine 
as the amine fragment, seem to be the most promising 
imidazolone-derived candidates for potential ABCB1-
modulators. 
Conclusion 
In this work, the series of new 5-arylideneimidazolone 
derivatives (7-23) with amine at position 2 (Group A) or 2 and 
3 (Group B), was explored in search for anticancer agents 
selectively active towards MDR cells and/or modulating 
ABCB1 efflux pump. These compounds were rationally 
designed and originally synthesized in the 3-5 steps synthetic 
pathways, followed by screening in vitro with the use of assays 
in PAR and MDR T-lymphoma cancer cells, involving MTT 
cytotoxicity- and rhodamine 123 accumulation assays,  
respectively. Active modulators found were also examined on 
their mode of action in Pgp‐Glo™ Assay. Pharmacophore-
based molecular modelling was performed as well as 
lipophilicity was examined using both experimental and in silico 
methods.  
The obtained results pointed out two compounds as the most 
promising anticancer agents overcoming MDR, i.e. (Z)-2-
amino-5-(4-fluorobenzylidene)-3-(3-morpholinopropyl)-4H-
imidazol-4-one hydrochloride (14) and (Z)-2-amino-5-(4-
fluorobenzylidene)-3-(3-(4-methylpiperazin-1-yl)propyl)-4H-
imidazol-4-one hydrochloride (15). These compounds turned 
out to be selective towards MDR T-lymphoma, and more 
potent than doxorubicin anticancer agents in the MTT 
cytotoxicity assays. Furthermore, (Z)-5-(3-((2,4-
dichlorobenzyl)oxy)benzylidene)-2-(4-morpholinopiperidin-1-
yl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (12) 
displayed the pump modulating activity nearly as potent as the 
third generation ABCB1 inhibitor, tariquidar, together with 
selective cytotoxic effects towards MDR cancer cells. Based 
on the biological results, new pharmacophore, postulating five 
structural features responsible for ABCB1 modulating 
properties in the considered chemical group, was designed. 
In view of the all results of this study, the considered chemical 
family of imidazolones seems to be very promising in search 
for new therapeutic approaches in the fight against resistant 
cancer diseases. Therefore, further extensive studies for the 
imidazolones are needed, in which compounds 12, 14, and 15 
may serve as parallel lead structures.  
Experimental Section 
Chemical synthesis 
Reagents were purchased from Sigma Aldrich (Darmstadt, Germany), 
Alfa Aesar (Karlsruhe, Germany) or Acros Organics (Geel, Belgium). 
Reactions progress were verified using thin layer chromatography 
(TLC). It was carried out on silica gel 60 F254 plates (0.2 mm Merck). 
UV light was used for spots visualization. MEL-TEMP II apparatus (LD 
Inc., Long Beach, CA, USA) was used to determine melting points (mp) 
and are uncorrected. The 1H-NMR spectra were obtained on a Mercury-
VX 300 Mz spectrometer (Varian, Palo Alto, CA, USA) or JOEL JNM-
ECZR500 RS1 (ECZR version) at 500 MHz. DMSO-d6 was used as 
deuterated solvent and internal standard. Chemical shifts (δ) are given 
in ppm (parts per million).Data are reported in following order: chemical 
shift, multiplicity (s - singlet; br. s - broad singlet; d - doublet; d def. – 
doublet deformed; dd – doublet of doublets; t - triplet; t def. - triplet 
deformated; qui - quintet; m - multiplet), coupling constant J  (Hz), 
protons’ number, position of particular protons (Ar- aromatic moiety at 
C5 of imidazolone, Pip-Ar – aromatic moiety linked to piperazine, Phth 
– phthalimide, Pp—piperidine, Mor – morpholine, Pip- piperazine, Ar-
Pip – piperazine linked with aromatic moiety). Mass spectra were 
obtained on a UPLC-MS/MS system consisted of a Waters 
ACQUITY®UPLC® (Waters Corporation, Milford, MA, USA) coupled to 
a Waters TQD mass spectrometer (electrospray ionization mode ESI-
tandem quadrupole). Chromatographic separations were performed 
with Acquity UPLC BEH (bridged ethyl hybrid) C18 column; 2.1 × 100 
mm, and 1.7 µm particle size, equipped with Acquity UPLC BEH C18 
VanGuard precolumn (Waters Corporation, Milford, MA, USA), 2.1 × 5 
mm and 1.7 µm particle size. The detailed separations conditions: 
temperature 40°C, elution under gradient from 95% to 0% of eluent A 
over 10 min, at a flow rate of 0.3 mL·min−1. Eluent A: water/formic acid 
(0.1%, v/v); eluent B: acetonitrile/formic acid (0.1%, v/v). Waters eλ 
PDA detector was used for chromatograms preparations. Spectra were 
analyzed in the range from 200 to 700 nm with 1.2 nm resolution and 
sampling rate 20 points/s. MS detection settings of Waters TQD mass 
spectrometer were as follows: source temperature 150°C, desolvation 
temperature 350° C, desolvation gas flow rate 600 L·h−1, cone gas flow 
100 L·h−1, capillary potential 3.00 kV, cone potential 40 V. For 
nebulization and as drying gas, nitrogen was used. The appropriate 
data were obtained in a scan mode in range between 50 and 1000 m/z 
in time 0.5 s intervals. MassLynx V 4.1 (Waters Corporation, Milford, 
MA, USA) software was used for data acquisition. Retention times (tR) 
are presented in minutes. The UPLC/MS analysis provided the purity 
information (%) of all the described compounds. Elemental analyses (C, 
H, N) for final compounds (7-23) were performed on an Elemental 
Analyser Vario El III (Hanau, Germany). Detailed procedure and 
synthesis conditions for intermediates 30, 31, 36, 38, 39, 44, and final 
product 7 were described previously [25,26]. Here, elemental analysis 
for compound 7 was additionally measured and the chemical formula 
estimated, as follows: anal. calcd for C23H26N4O2·3HCl·0.5H2O: C, 
54.28; H, 5.95; N, 11.01; found: C, 54.07; H, 6.10; N, 10.87. 
General procedure to obtain aminepropylphthalimide derivative (24)  
2-(3-Bromopropyl)isoindoline-1,3-dione (50 mmol, 13.40 g), 1-
phenylpiperazine (50 mmol, 8.11 g), potassium carbonate (150 mmol, 
20.73 g), TEBA (5 mmol, 1.15 g) and acetone (150 ml) were put into 
flat-bottom flask. The reaction mixture was heated under reflux and 
stirred for 5 hours. Then, it was stirred at room temperature for 72 hours. 
The reaction mixture was filtered off. The resulted filtrate was 
evaporated, extracted with methylene chloride, dried over magnesium 
sulphate. After that, filtration and evaporation were performed. Solid 
precipitated after cooling in the fridge. 
2-(3-(4-Phenylpiperazin-1-yl)propyl)isoindoline-1,3-dione (24) 
Yellow solid. Yield 66 %; mp 113-116 °C. C21H23N3O2 MW 349.43. 1H-
NMR (DMSO-d6, ppm): δ 7.84 – 7.80 (m, 2H, Phth-4,5-H), 7.77 – 7.73 
(m, 2H, Phth-6,7-H), 7.14 – 7.10 (m, 2H, Pip-Ar-3,5-H), 6.81 – 6.76 (m, 
2H, Pip-Ar-2,6-H), 6.72 – 6.67 (m, 1H, Pip-Ar-4-H), 3.65-3.59 (t, J = 6.8 
Hz, 2H, Pip-CH2-CH2-CH2), 2.89-2.82 (t def., 4H, Ar-Pip-2,6-H), 2.38 – 
2.29 (m, 6H, Ar-Pip-3,5-H, Pip-CH2), 1.78-1.70 (qui, J = 6.7 Hz, 2H, Pip-
CH2-CH2). LC/MS±: purity  % tR = 4.02, (ESI) m/z [M+H]+ 350.30. 
4.1.2. General procedure to obtain primary amine from phthalimide 
derivative (25)  
The mixture of 2-(3-(4-phenylpiperazin-1-yl)propyl)isoindoline-1,3-
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anhydrous ethanol (145 ml) was stirred and refluxed for 6 hours. Then, 
it was stirred at room temperature for 72 hours. After that, the reaction 
mixture was filtered off; the resulted filtrate was evaporated. Extraction 
with methylene chloride was performed. After drying over sodium 
sulphate, filtration and evaporation, pure product was obtained. 
3-(4-Phenylpiperazin-1-yl)propan-1-amine (25) 
Cream oil. Yield 53 %. C13H21N3 MW 219.33. 1H-NMR (DMSO-d6, 
ppm): δ 7.21 – 7.11 (m, 2H, Pip-Ar-3,5-H), 6.86 (d def., 2H, Pip-Ar-2,6-
H), 6.76 – 6.69 (m, 1H, Pip-Ar-4-H), 3.11-3.01 (t def., 4H, Ar-Pip-2,6-H, 
H3O+), 2.62 – 2.49 (t def., 2H, Pip-CH2-CH2-CH2), 2.38-2.34 (t def., 4H, 
Ar-Pip-3,5-H), 2.34 – 2.20 (m, 2H, Pip-CH2), 1.53-1.37 (m, 2H, Pip-CH2-
CH2). LC/MS±: purity 95 % tR = 1.36, (ESI) m/z [M+H]+ 220.24. 
4.1.3. General procedure to obtain 3-benzyloxybenzaldehydes (26-29) 
3-Hydroxybenzaldehyde (50 mmol, 6.11 g), benzyl chloride or benzyl 
bromide (50 mmol), potassium carbonate (25 mmol, 3.45 g) and 
ethanol (50 ml) was put into flask and refluxed for 6 hours. Then, the 
reaction mixture was cooled down to room temperature and filtered. 
The filtrate was evaporated and then extracted using methylene 
chloride and washed with 1 % NaOH (twice) and water (one time). It 
was dried over magnesium sulphate, filtered and evaporated. 
3-(Benzyloxy)benzaldehyde (26)  
3-Hydroxybenzaldehyde (50 mmol, 6.11 g) and benzyl chloride (50 
mmol, 6.33 g) were used. White solid. Yield 36 %; mp 48-50 °C. 
C14H12O2 MW 212.24. 1H-NMR (DMSO-d6, ppm): δ 9.97 (s, 1H, Ar-
CHO), 7.56-7.51 (m, 3H, Ar-2,5,6-H), 7.49-7.45 (m, 2H, Ar`-2,6-H), 
7.42-7.38 (m, 2H, Ar`-3,5-H), 7.37-7.32 (m, 2H, Ar-4-H, Ar`-4-H), 5.19 
(s, 2H, O-CH2). LC/MS±: purity 98.35 % tR = 7.07, (ESI) m/z [M+H]+ 
213.20. 
3-(4-Fluorobenzyloxy)benzaldehyde (27)  
3-Hydroxybenzaldehyde (50 mmol, 6.11 g) and 4-fluorobenzyl chloride 
(50 mmol, 7.23 g) were used. Light orange solid. Yield 40 %; mp 58-
60 °C. C14H11FO2 MW 230.24. 1H-NMR (DMSO-d6, ppm): 9.94 (s, 1H, 
Ar-CHO), 7.88-7.39 (m, 5H, Ar-2,5,6-H, Ar`-2,6-H), 7.37-7.27 (m, 1H, 
Ar-4-H), 7.25-7.01 (t def., 2H, Ar`-3,5-H), 5.14 (s, 2H, O-CH2). LC/MS±: 
purity 100.00 % tR = 7.10, (ESI) m/z [M+H]+ 231.14. 
3-(4-Chlorobenzyloxy)benzaldehyde (28)  
3-Hydroxybenzaldehyde (50 mmol, 6.11 g) and 4-chlorobenzyl bromide 
(50 mmol, 10.27 g) were used. White solid. Yield 19 %; mp 43-45 °C. 
C14H11ClO2 MW 246.69. 1H-NMR (DMSO-d6, ppm): δ 9.94 (s, 1H, CHO), 
7.51-7.48 (m, 2H, Ar`-3,5-H), 7.48-7.41 (m, 5H, Ar-2,4,6-H, Ar`-2,6-H), 
7.34-7.29 (m, 1H, Ar-5-H), 5.16 (s, 2H, O-CH2). LC/MS±: purity 96.69 % 
tR = 7.76, (ESI) m/z [M+H]+ 247.17. 
3-(2,4-Dichlorobenzyloxy)benzaldehyde (29) 
3-Hydroxybenzaldehyde (50 mmol, 6.11 g) and 2,4-dichlorobenzyl 
chloride (50 mmol, 9.77 g) were used. Cream solid. Yield 26 %; mp 69-
71 °C. C14H10Cl2O2 MW 281.13. 1H-NMR (DMSO-d6, ppm): δ 9.95 (s, 
1H, CHO), 7.76-7.67 (d def., 1H, Ar`-3-H), 7.65-7.60 (d def., 1H, Ar`-6-
H), 7.57-7.52 (m, 2H, Ar-2,6-H), 7.50-7.49 (m, 1H, Ar-4-H), 7.47-7.40 
(m, 1H, Ar`-5-H), 7.36-7.29 (m, 1H, Ar-5-H), 5.20 (s, 2H, O-CH2). 
LC/MS±: purity 100.00 % tR = 8.47, (ESI) m/z [M+H]+ 281.26. 
4.1.4. General procedure of Knoevenagel condensation (32-35, 37) 
Thiohydantoin (10-31 mmol, 1.16-3.60 g), proper aldehyde (10-31 
mmol), sodium acetate (10-31 mmol, 0.82-2.54 g), and acetic acid (10-
31 ml) was added to flat-bottom flask and heated under reflux for 5.5 
hours and then stirred at room temperature for next 20 hours. The 
reaction mixture was filtered to provide product which was further 
purified via crystallization from acetic acid if necessary. 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-thioxoimidazolidin-4-one (32) 
2-Thiohydantoin (19 mmol, 2.20 g) and 3-(benzyloxy)benzaldehyde 
(26) (19 mmol, 4.03 g) were used. Brown solid. Yield 99 %; mp 211-
213 °C. C17H14N2O2S MW 310.37. 1H-NMR (DMSO-d6, ppm): δ 12.36 
(s, 1H, N1-H), 12.17 (s, 1H, N3-H), 7.46-7.41 (m, 2H, Ar`-2,6-H), 7.39-
7.35 (m, 2H, Ar`-3,5-H), 7.33-7.28 (m, 4H, Ar-2,5,6-H, Ar`-4-H), 7.02- 
6.97 (m, 1H, Ar-4-H), 6.41 (s, 1H, C=CH), 5.14 (s, 2H, O-CH2). LC/MS±: 
purity 96.64 % tR = 6.60, (ESI) m/z [M+H]+ 311.22. 
(Z)-5-(3-((4-Fluorobenzyl)oxy)benzylidene)-2-thioxoimidazolidin-4-one 
(33) 
2-Thiohydantoin (20 mmol, 2.32 g) and 3-((4-
fluorobenzyl)oxy)benzaldehyde (27) (20 mmol, 4.60 g) were used. 
Yellow solid. Yield 80 %; mp 220-223 °C. C17H13FN2O2S MW 328.36. 
1H-NMR (DMSO-d6, ppm): δ 12.27 (s, 1H, N1-H), 12.04 (s, 1H, N3-H), 
7.73-7.67 (d def., 2H, Ar`-2,6-H), 7.51-7.44 (m, 2H, Ar-4,6-H), 7.23-7.15 
(m, 2H, Ar-2,5-H), 7.04-6.98 (d def., 2H, Ar`-3,5-H), 6.43 (s, 1H, C=CH), 




2-Thiohydantoin (10 mmol, 1.16 g) and 3-((4-
chlorobenzyl)oxy)benzaldehyde (28) (10 mmol, 2.46 g) were used. 
Brown solid. Yield 79 %; mp 223-225 °C. C17H13ClN2O2S MW 344.81. 
1H-NMR (DMSO-d6, ppm): δ 12.36 (s, 1H, N1-H), 12.17 (s, 1H, N3-H), 
7.48-7.40 (m, 4H, Ar`-2,3,5,6-H), 7.34-7.27 (m, 3H, Ar-2,5,6-H), 7.02-
6.97 (m, 1H, Ar-4-H), 6.41 (s, 1H, C=CH), 5.14 (s, 2H, O-CH2). LC/MS±: 
purity 98.70 % tR = 7.23, (ESI) m/z [M+H]+ 345.21. 
(Z)-5-(3-((2,4-Dichlorobenzyl)oxy)benzylidene)-2-thioxoimidazolidin-4-
one (35) 
2-Thiohydantoin (31 mmol, 3.60 g) and 3-((2,4-
dichlorobenzyl)oxy)benzaldehyde (29) (31 mmol, 8.72 g) were used. 
Yellow solid. Yield 88 %; mp 190-192 °C. C17H12Cl2N2O2S MW 379.26. 
1H-NMR (DMSO-d6, ppm): δ 12.37 (s, 1H, N1-H), 12.20 (s, 1H, N3-H), 
7.88-7.67 (d def., 1H, Ar`-3-H), 7.62-7.58 (d def., 1H, Ar`-6-H), 7.54-
7.45 (m, 1H, Ar`-5-H), 7.41-7.11 (m, 3H, Ar-2,5,6-H), 7.06-6.84 (m, 1H, 
Ar-4-H), 6.42 (s, 1H, C=CH), 5.18 (s, 2H, O-CH2). LC/MS±: purity 
99.39 % tR = 7.92, (ESI) m/z [M+H]+ 379.09. 
(Z)-5-(4-Fluorobenzylidene)-2-thioxoimidazolidin-4-one (37) 
2-Thiohydantoin (25 mmol, 2.90 g) and 4-fluorobenzaldehyde (25 mmol, 
3.10 g) were used. Yellow solid. Yield 84 %; mp 253-257 °C. 
C10H7FN2OS MW 222.24. 1H-NMR (DMSO-d6, ppm): δ 12.64-11.98 (d 
def., 2H, N1-H, N3-H), 7.87-7.68 (m, 2H, Ar-2,6-H), 7.32-7.14 (m, 2H, 
Ar-3,5-H), 6.46 (s, 1H, C=CH). LC/MS±: purity 100.00 % tR = 4.47, (ESI) 
m/z [M+H]+ 223.04. 
4.1.5. General procedure of S-methylation (40-43, 45) 
Firstly, sodium (0.16-0.61 g, 7-26.5 mmol) was dissolved in ethanol 
(10.85-39.75 mL). To this solution, appropriate 5–
arylidenethiohydantion (7-26.5 mmol) was added. After 3 minutes, 
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mixture was stirred at room temperature for 24 hours. Filtration was 
performed to provide product, which was further purified via 
crystallization from acetone, if necessary. 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (40) 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-thioxoimidazolidin-4-one (32) (17 
mmol, 5.28 g) and iodomethane (17 mmol, 2.58 g) were used. Yellow 
solid. Yield 48 %; mp 233-235 °C. C18H16N2O2S MW 324.40. 1H-NMR 
(DMSO-d6, ppm): δ 11.81 (s, 1H, N3-H), 8.00 (s, 1H, Ar-2-H), 7.67-7.62 
(d def., 1H, Ar-6-H), 7.44-7.41 (m, 2H, Ar`-2,6-H), 7.39-7.34 (m, 2H, 
Ar`-3,5-H), 7.33-7.27 (m, 2H, Ar-5-H, Ar`-4-H), 7.02-6.97 (m, 1H, Ar-4-
H), 6.67 (s, 1H, C=CH), 5.11 (s, 2H, O-CH2), 2.61 (s, 3H, CH3). 




(33) (16 mmol, 5.25 g) and iodomethane (16 mmol, 2.43 g) were used. 
Yellow solid. Yield 30 %; mp 180-182 °C. C18H15FN2O2S MW 342.39. 
1H-NMR (DMSO-d6, ppm): δ 11.82 (s, 1H, N3-H), 7.99 (s, 1H, Ar-2-H), 
7.68-7.64 (d, J = 13.8 Hz, 1H, Ar-6-H), 7.50 – 7.45 (m, 2H, Ar`-2,6-H), 
7.33-7.28 (t, J = 22.4 Hz, 1H, Ar-5-H), 7.21 – 7.16 (m, 2H, Ar`-3,5-H), 
6.98 (m, 1H, Ar-4-H), 6.67 (s, 1H, C=CH), 5.09 (s, 2H, O-CH2), 2.61 (s, 




(34) (7 mmol, 2.41 g) and iodomethane (7 mmol, 1.06 g) were used. 
Yellow solid. Yield 83 %; mp 108-110 °C. C18H15ClN2O2S MW 358.84. 
1H-NMR (DMSO-d6, ppm): δ 11.83 (s, 1H, N3-H), 7.98 (s, 1H, Ar-2-H), 
7.87-7.62 (d def., 1H, Ar-6-H), 7.61-7.34 (m, 4H, Ar`-2,3,5,6-H), 7.32-
7.14 (t def., 1H, Ar-5-H), 7.05-6.89 (m, 1H, Ar-4-H), 6.66 (s, 1H, C=CH), 
5.11 (s, 2H, O-CH2), 2.60 (s, 3H, CH3). LC/MS±: purity 95.17 % tR = 




one (35) (26.5 mmol, 10.05 g) and iodomethane (26.5 mmol, 4.03 g) 
were used. Yellow solid. Yield 61 %; mp 181-183 °C. C18H14Cl2N2O2S 
MW 393.28. 1H-NMR (DMSO-d6, ppm): δ 8.08 (s, 1H, Ar-2-H), 7.68-
7.64 (d, J = 2.1 Hz, 1H, Ar`-3-H), 7.61-7.58 (d, J = 8.3 Hz, Ar`-6-H), 
7.57-7.53 (d, J = 7.7 Hz, Ar`-5-H), 7.48-7.43 (dd, J = 8.3, 2.3 Hz, 1H, 
Ar-6-H), 7.31-7.25 (t, J = 7.9 Hz, 1H, Ar-5-H), 6.97-6.92 (dd, J = 8.0, 
2.3 Hz, 1H, Ar-4-H), 6.48 (s, 1H, C=CH), 5.14 (s, 2H, O-CH2), 2.54 (s, 
3H, CH3). LC/MS±: purity 92.74 % tR = 8.88 (ESI) m/z [M+H]+ 393.10. 
(Z)-5-(4-Fluorobenzylidene)-2-(methylthio)-4H-imidazol-4-one (45) 
(Z)-5-(4-Fluorobenzylidene)-2-thioxoimidazolidin-4-one (37) (20 mmol, 
4.44 g) and iodomethane (20 mmol, 3.04 g) were used. Yellow solid. 
Yield 97 %; mp 242-245 °C. C11H9FN2OS MW 236.26. 1H-NMR 
(DMSO-d6, ppm): δ 11.80 (br. s, 1H, N3-H) , 8.32-8.14 (m, 2H, Ar-2,6-
H), 7.32-7.15 (m, 2H, Ar-3,5-H), 6.72 (s, 1H, C=CH), 2.62 (s, 3H, CH3). 
LC/MS±: purity 98.36 % tR = 5.92, (ESI) m/z [M+H]+ 237.12. 
4.1.6. General procedure to obtain 5-arylideneimidazolone final 
products (8-23) 
(Z)-2-(Methylthio)-5-arylidene-4H-imidazol-4-one (2-5 mmol) and 
proper amine (2.5-6 mmol) were heated and stirred in oil bath with 
controlled temperature (125°C) for 15 minutes. After that time, ethanol 
(15 ml) was added. The mixture was stirred and heated under reflux for 
5-6 hours. Then, it was stirred at room temperature for 20 hours. After 
that, gaseous hydrochloride acid was used for conversion of obtained 
products into hydrochloride form. If necessary, purification was 
performed using crystallization from ethanol. 
(Z)-5-(Naphthalen-2-ylmethylene)-2-(4-morpholinopiperidin-1-yl)-3,5-
dihydro-4H-imidazol-4-one hydrochloride (8) 
(Z)-5-(Naphthalen-2-ylmethylene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (39) (5 mmol, 1.34 g) and 4-morpholinopiperidine (6 
mmol, 1.02 g) were used. Yellow solid. Yield 98 %; mp 215-217°C. 
C23H26N4O2·2HCl·1.5H2O MW 490.42. 1H-NMR (DMSO-d6, ppm): δ 
11.82 (s, 1H, NH+), 8.38 (s, 1H, N3-H), 8.11- 7.98 (d def., 1H, Ar-1-H), 
7.96-7.82 (m, 4H, Ar-3,4,5,8-H), 7.57-7.46 (m, 2H, Ar-6,7-H), 6.77 (s, 
1H, C=CH), 4.90- 3.61 (m, 6H, Mor-2,6-Hb, Mor-3,5-H, H3O+) , 3.55-
3.43 (m, 1H, Pp-4-H), 3.41-3.33 (d def., 2H, Mor-2,6-Ha), 3.29-3.16 (t, 
J = 12.3 Hz, 2H, Pp-2,6-Hb), 3.13-2.97 (m, 2H, Pp-2,6-Ha), 2.33-2.22 (d 
def., 2H, Pp-3,5-Hb), 1.91-1.77 (m, 2H, Pp-3,5-Ha). LC/MS±: purity 
100.00 % tR = 3.97, (ESI) m/z [M+H]+ 391.35. Anal. calcd for 
C23H26N4O2·2HCl·1.5H2O: C, 56.33; H, 6.38; N, 11.43; found: C, 56.02; 
H, 6.29; N, 11.29.  
(Z)-5-(3-(Benzyloxy)benzylidene)-2-(4-morpholinopiperidin-1-yl)-3,5-
dihydro-4H-imidazol-4-one hydrochloride (9) 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (40) (5 mmol, 1.62 g) and 4-morpholinopiperidine (6 
mmol, 1.02 g) were used. Yellow solid. Yield 91 %; mp 230-232°C. 
C26H30N4O3·2HCl·1.5H2O MW 546.49. 1H-NMR (DMSO-d6, ppm): δ 
11.85 (s, 1H, NH+), 7.55 (s, 1H, N3-H), 7.46-7.34 (m, 6H, Ar-2,6-H, Ar`-
2,3,5,6-H), 7.32-7.27 (m, 2H, Ar-5-H, Ar`-4-H), 7.00-6.94 (dd, J = 8.2, 
2.1 Hz, 1H, Ar-4-H), 6.57 (s, 1H, C=CH), 5.13 (s, 2H, O-CH2), 3.94-3.85 
(m, 6H, Mor-3,5-H, Mor-2,6-Hb, H3O+), 3.51-3.41 (m, 1H, Pp-4-H), 3.39-
3.29 (d def., 2H, Mor-2,6-Ha), 3.24-3.11 (t, J = 12.5 Hz, 2H, Pp-2,6-Hb), 
3.08-2.93 (m, 2H, Pp-2,6-Ha), 2.32-2.18 (d def., 2H, Pp-3,5-Hb), 1.91-
1.73 (m, 2H, Pp-3,5-Ha). LC/MS±: purity 97.19 % tR = 4.75, (ESI) m/z 
[M+H]+ 447.40. Anal. calcd for C26H30N4O3·2HCl·1.5H2O: C, 57.14; H, 
6.47; N, 10.25; found: C, 57.11; H, 6.33; N, 10.21. 
(Z)-5-(3-(4-Fluorobenzyloxy)benzylidene)-2-(4-morpholinopiperidin-1-
yl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (10) 
(Z)-5-(3-(4-Fluorobenzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-
4H-imidazol-4-one (41) (3 mmol, 1.03 g) and 4-morpholinopiperidine 
(3.5 mmol, 0.60 g) were used. Yellow solid. Yield 86 %; mp 228-230 °C. 
C26H29FN4O3·2HCl·H2O MW 555.47. 1H-NMR (DMSO-d6, ppm): δ 
11.76 (s, 1H, NH+), 7.87-7.76 (d, J=7.8 Hz, 2H, Ar`-2,6-H) , 7.53-7.44 
(m, 2H, Ar-2,6-H), 7.24-7.15 (m, 2H, Ar-4,5-H), 7.07-7.00 (d, J = 7.0 Hz, 
2H, Ar`-3,5-H), 6.63 (s, 1H, C=CH), 5.12 (s, 2H, O-CH2), 4.51-2.89 (m, 
13H, Pp-2,4,6-H, Mor, H3O+), 2.29-2.20 (d def., 2H, Pp-3,5-Hb), 1.89-
1.73 (m, 2H, Pp-3,5-Ha). LC/MS±: purity 98.57 % tR = 4.55, (ESI) m/z 
[M+H]+ 465.35. Anal. calcd for C26H29FN4O3·2HCl·H2O: C, 56.22; H, 
6.00; N, 10.09; found: C, 55.85; H, 5.76; N, 9.88. 
(Z)-5-(3-(4-Chlorobenzyloxy)benzylidene)-2-(4-morpholinopiperidin-1-
yl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (11) 
(Z)-5-(3-(4-Chlorobenzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-
4H-imidazol-4-one (42) (3 mmol, 1.08 g) and 4-morpholinopiperidine (4 
mmol, 0.68 g) were used. Cream solid. Yield 88 %; mp 208-210 °C. 
C26H29ClN4O3·2HCl·2.5H2O MW 598.94. 1H-NMR (DMSO-d6, ppm): δ 
11.76 (s, 1H, NH+), 7.56 (s, 1H, N3-H), 7.47-7.39 (m, 6H, Ar-2,6-H, Ar`-
2,3,5,6-H), 7.32-7.27 (t, J = 8.0 Hz, 1H, Ar-5-H), 6.97-6.92 (dd, J = 8.2, 
2.0 Hz, 1H, Ar-4-H), 6.53 (s, 1H, C=CH), 5.13 (s, 2H, O-CH2), 3.96-3.83 
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3.32 (d def., 2H, Mor-2,6-Ha), 3.21-3.10 (t, J = 11.9 Hz, 2H, Pp-2,6-Hb), 
3.08-2.99 (m, 2H, Pp-2,6-Ha), 2.29-2.20 (d def., 2H, Pp-3,5-Hb), 1.84-
1.73 (m, 2H, Pp-3,5-Ha). LC/MS±: purity 100.00 % tR = 5.19, (ESI) m/z 
[M+H]+ 481.50. Anal. calcd for C26H29ClN4O3·2HCl·2.5H2O: C, 52.14; H, 





dihydro-4H-imidazol-4-one (43) (3 mmol, 1.18 g) and 4-
morpholinopiperidine (3.5 mmol, 0.60 g) were used. Cream solid. Yield 
56 %; mp 213-215 °C. C26H28Cl2N4O3·2HCl·3.5H2O MW 651.41. 1H-
NMR (DMSO-d6, ppm): δ 11.71 (s, 1H, NH+), 7.70-7.67 (d, J = 2.1 Hz, 
1H, Ar-2-H), 7.67-7.62 (m, 1H, Ar`-3-H), 7.59-7.55 (d, J = 8.3 Hz, 1H, 
Ar`-5-H), 7.48-7.44 (dd, J = 8.3, 2.1 Hz, Ar-6-H), 7.42-7.38 (d def. 1H, 
Ar`-6-H), 7.35-7.28 (t, J = 7.9 Hz, 1H, Ar-5-H), 7.01-6.95 (dd, J = 8.0, 
1.8 Hz, 1H, Ar-4-H), 6.53 (s, 1H, C=CH), 5.18 (s, 2H, O-CH2), 3.99-3.82 
(m, 6H, Mor-3,5-H, Mor-2,6-Hb, H3O+), 3.50-3.41 (m, 1H, Pp-4-H), 3.39-
3.30 (d def., 2H, Mor-2,6-Ha), 3.22-2.99 (m, 4H, Pp-2,6-H), 2.28-2.19 
(d def., 2H, Pp-3,5-Hb), 1.85-1.73 (m, 2H, Pp-3,5-Ha). LC/MS±: purity 
94.19 % tR = 5.70, (ESI) m/z [M+H]+ 515.33. Anal. calcd for 
C26H28Cl2N4O3·2HCl·3.5H2O: C, 47.94; H, 5.74; N, 8.60; found: C, 
47.96; H, 5.33; N, 8.42. 
(Z)-5-(Phenanthren-9-ylmethylene)-2-(4-morpholinopiperidin-1-yl)-3,5-
dihydro-4H-imidazol-4-one hydrochloride (13) 
(Z)-5-(Phenanthren-9-ylmethylene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (44) (5 mmol, 1.60 g) and 4-morpholinopiperidine (6 
mmol, 1.02 g) were used. Yellow solid. Yield 92 %; mp 275-277 °C. 
C27H28N4O2·3HCl·3.5H2O MW 612.98. 1H-NMR (DMSO-d6, ppm): δ 
11.89 (s, 1H, NH+), 8.93-8.86 (d def., 1H, Ar-1-H), 8.85-8.80 (d, J = 8.8 
Hz, 1H, Ar-8-H), 8.43 (s, 1H, N3-H), 8.17- 8.11 (d def., 1H, Ar-4-H), 
8.03-7.96 (d def., 1H, Ar-5-H), 7.77-7.61 (m, 5H, Ar-2,3,6,7,10-H), 7.29 
(s, 1H, C=CH), 4.66-2.98 (m, 13H, Pp-2,4,6-H, Mor, H3O+), 2.32-2.20 
(d def., 2H, Pp-3,5-Hb), 1.98-1.74 (m, 2H, Pp-3,5-Ha). LC/MS±: purity 
97.37 % tR = 4.51, (ESI) m/z [M+H]+ 441.35. Anal. calcd for 
C27H28N4O2·3HCl·3.5H2O: C, 52.90; H, 6.26; N, 9.14; found: C, 52.97; 
H, 5.75; N, 9.03.  
(Z)-2-Amino-5-(4-fluorobenzylidene)-3-(3-morpholinopropyl)-4H-
imidazol-4-one hydrochloride (14) 
(Z)-5-(4-Fluorobenzylidene)-2-(methylthio)-4H-imidazol-4-one (45) (5 
mmol, 1.18 g) and 3-morpholinopropan-1-amine (6 mmol, 0.87 g) were 
used. Yellow solid. Yield 60 %; mp 248-251°C. C17H21FN4O2·2HCl·H2O 
MW 423.311H-NMR (DMSO-d6, ppm): δ 8.05 (s, 2H, Ar-2,6-H), 7.42 (br. 
s, 1H, N3-H), 7.19-7.09 (t, , J = 8.8 Hz, 2H, Ar-3,5-H), 6.23 (s, 1H, 
C=CH), 3.58-3.52 (t, J= 4.6 Hz, 4H, Mor-3,5-H), 3.42-3.11 (m, 4H, Mor-
2,6-H, H3O+), 2.39-2.14 (m, 4H, N3-CH2-CH2-CH2), 1.68 (s, 2H, N3-
CH2-CH2). LC/MS±: purity 98.64 % tR = 2.93, (ESI) m/z [M+H]+ 333.29.  
Anal. calcd for C17H21FN4O2·2HCl·H2O: C, 48.23; H, 5.96; N, 13.24; 
found: C, 48.52; H, 5.75; N, 13.34. 
(Z)-2-Amino-5-(4-fluorobenzylidene)-3-(3-(4-methylpiperazin-1-
yl)propyl)-4H-imidazol-4-one hydrochloride (15) 
(Z)-5-(4-Fluorobenzylidene)-2-(methylthio)-4H-imidazol-4-one (45) (5 
mmol, 1.18 g) and 3-(4-methylpiperazin-1-yl)propan-1-amine (6 mmol, 
0.94 g) were used. Yellow solid. Yield 99 %; mp 254-257 °C. 
C18H24FN5O·3HCl·3H2O MW 508.84. 1H-NMR (DMSO-d6, ppm): δ 8.04 
(s, 2H, Ar-2,6-H), 7.41 (br. s, 1H, N3-H), 7.21-7.08 (t def., 2H, Ar-3,5-
H), 6.22 (s, 1H, C=CH), 3.32 (s, 2H, N3-CH2, H3O+), 2.42-2.15 (m, 10H, 
Pip, N3-CH2-CH2-CH2), 2.12 (s, 3H, Pip-N-CH3), 1.67 (s, 2H, N3-CH2-
CH2). LC/MS±: purity 98.50 % tR = 2.56, (ESI) m/z [M+H]+ 346.31. Anal. 
calcd for C18H24FN5O·3HCl·3H2O: C, 42.48; H, 6.55; N, 13.77; found: 
C, 42.73; H, 6.05; N, 14.06. 
(Z)-2-Amino-5-(4-fluorobenzylidene)-3-(3-(4-phenylpiperazin-1-
yl)propyl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (16) 
(Z)-5-(4-Fluorobenzylidene)-2-(methylthio)-4H-imidazol-4-one (45) (3 
mmol, 0.71 g) and 3-(4-phenylpiperazin-1-yl)propan-1-amine (25) (4 
mmol, 0.88 g) were used. Yellow solid. Yield 81 %; mp 188-190 °C. 
C23H26FN5O·3HCl MW 516.87. 1H-NMR (DMSO-d6, ppm): δ 11.35 (br. 
s, 1H, NH+), 9.56 (s, 1H, N3-H), 7.91-7.75 (m, 2H, Ar-2,6-H), 7.33-7.19 
(m, 4H, Ar-3,5-H, Pip-Ar-3,5-H), 7.00-6.95 (d def., 2H, Pip-Ar-2,6-H), 
6.85-6.76 (m, 2H, C=CH, Pip-Ar-4-H), 3.87-3.42 (m, 6H, N-CH2, Ar-Pip-
2,6-H), 3.29-2.99 (m, 6H, N-CH2-CH2-CH2, Ar-Pip-3,5-H), 2.20-2.01 (m, 
2H, N-CH2-CH2). LC/MS±: purity 99.74 % tR = 4.50, (ESI) m/z [M+H]+ 
408.39. Anal. calcd for C23H26FN5O·3HCl: C, 53.44; H, 5.67; N, 13.55; 
found: C, 53.35; H, 5.69; N, 13.51. 
(Z)-2-Amino-5-(3-(benzyloxy)benzylidene)-3-(2-morpholinoethyl)-3,5-
dihydro-4H-imidazol-4-one hydrochloride (17) 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (40) (4 mmol, 1.30 g) and 2-morpholinoetan-1-amine (6 
mmol, 0.79 g) were used. Cream solid. Yield 80 %; mp 203-205 °C. 
C23H26N4O3·2HCl·H2O MW 497.42. 1H-NMR (DMSO-d6, ppm): δ 11.43 
(br. s, 1H, NH+), 8.42 (br. s, 1H, N3-H), 7.55-7.41 (m, 3H, Ar-2-H, Ar`-
2,6-H), 7.39-7.24 (m, 5H, Ar-5,6-H, Ar`-3,4,5-H), 7.09-6.86 (m, 1H, Ar-
4-H), 6.71 (br. s, 1H, C=CH), 5.21-5.09 (m, 2H, O-CH2), 4.00-3.66 (d 
def., 6H, N-CH2, Mor-3,5-H) 3.50-2.96 (m, 6H, N3-CH2-CH2, Mor-2,6-
H, H3O+). LC/MS±: purity 98.62 % tR = 4.70, (ESI) m/z [M+H]+ 407.50. 
Anal. calcd for C23H26N4O3·2HCl·H2O: C, 55.53; H, 6.09; N, 11.27; 
found: C, 55.50; H, 6.01; N, 11.68.  
(Z)-2-Amino-5-(3-(benzyloxy)benzylidene)-3-(3-morpholinopropyl)-3,5-
dihydro-4H-imidazol-4-one hydrochloride (18) 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (40) (3 mmol, 0.97 g) and 3-morpholinopropan-1-amine 
(3.5 mmol, 0.50 g) were used. Yellow solid. Yield 77 %; mp 150-152 °C. 
C24H28N4O3·2HCl·1.5H2O MW 520.45. 1H-NMR (DMSO-d6, ppm): δ 
11.28 (br. s, 1H, NH+), 9.51 (br. s, 1H, N3-H), 7.48-7.40 (d def., 2H, Ar`-
2,6-H), 7.39-7.23 (m, 6H, Ar-2,5,6-H, Ar`-3,4,5-H), 7.07-6.93 (m, 1H, 
Ar-4-H), 6.70 (s, 1H, C=CH), 5.23-5.08 (m, 2H, O-CH2), 3.99-2.80 (m, 
12H, Mor, N3-CH2, N3-CH2-CH2-CH2, H3O+), 2.11-1.96 (m, 2H, N3- 
CH2-CH2). LC/MS±: purity 97.01 % tR = 4.74, (ESI) m/z [M+H]+ 421.53. 
Anal. calcd for C24H28N4O3·2HCl·1.5H2O: C, 55.38; H, 6.40; N, 10.77; 
found: C, 54.95; H, 6.24; N, 10.69. 
(Z)-2-Amino-5-(3-(benzyloxy)benzylidene)-3-(3-(4-methylpiperazin-1-
yl)propyl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (19) 
(Z)-5-(3-(Benzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-4H-
imidazol-4-one (40) (4 mmol, 1.30 g) and 3-(4-methylpiperazin-1-
yl)propan-1-amine (5.5 mmol, 0.865 g) were used. Cream solid. Yield 
41 %; mp 229-231 °C. C25H31N2O5·3HCl·0.5H2O MW 551.94. 1H-NMR 
(DMSO-d6, ppm): δ 12.14 (br. s, 1H, NH+), 9.66 (s, 1H, N3-H), 7.64-
7.23 (m, 8H, Ar-2,5,6-H, Ar`-2,3,4,5,6-H), 7.09-6.94 (d def., 1H, Ar-4-
H), 6.78-6.61 (d def., 1H, C=CH), 5.27-5.10 (d def., 2H, O-CH2), 4.39-
2.99 (m, 12H, Pip, N3-CH2, N3-CH2-CH2-CH2, , 2.79 (s, 3H, Pip-N-CH3), 
2.03(s, 2H, N3- CH2-CH2). 12.15 (br. s, 1H, NH+), 9.66 (s, 1H, NH), 
7.60-7.24 (m, 9H, Ar-H, Ar`-H), 7.09-6.59 (d def., 1H, C=NH), 6.78-6.73 
(d def., 1H, C=CH), 5.28-5.09 (d def., 2H, O-CH2), 3.98-3.04 (m, 12H, 
Pip, N3-CH2, N3-CH2-CH2-CH2, H3O+), 2.79 (s, 3H, Pip-N-CH3), 2.03 
(s, 2H, N3- CH2-CH2). LC/MS±: purity 98.73 % tR = 4.18, (ESI) m/z 
[M+H]+ 434.38. Anal. calcd for C25H31N2O5·3HCl·0.5H2O: C, 54.40; H, 
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morpholinopropyl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (20) 
(Z)-5-(3-(4-Fluorobenzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-
4H-imidazol-4-one (41) (3 mmol, 1.03 g) and 3-morpholinopropan-1-
amine (4 mmol, 0.58 g) were used. Yellow solid. Yield 57 %; mp 201-
203 °C. C24H27FN4O3·2HCl·H2O MW 529.43. 1H-NMR (DMSO-d6, 
ppm): δ 9.31 (s, 1H, N3-H), 7.70 (s, 2H, Ar-2,5-H), 7.51-7.44 (m, 2H, 
Ar`-2,6-H), 7.22-7.16 (m, 2H, Ar`-3,5-H), 7.12-7.01 (d def., 2H, Ar-4,6-
H), 6.73 (s, 1H, C=CH), 5.13 (s, 2H, O-CH2), 4.01-2.82 (m, 12H, Mor, 
N3-CH2, N3-CH2-CH2-CH2, H3O+), 2.02 (s, 2H, N3- CH2-CH2). LC/MS±: 
purity 98.65 % tR = 4.53, (ESI) m/z [M+H]+ 439.36. Anal. calcd for 
C24H27FN4O3·2HCl·H2O: C, 54.44; H, 5.91; N, 10.58; found: C, 54.63; 





4H-imidazol-4-one (41) (2 mmol, 0.68 g) and 3-(4-methylpiperazin-1-
yl)propan-1-amine (2.5 mmol, 0.39 g) were used. Yellow solid. Yield 
77 %; mp 229-231 °C. C25H30FN5O2·3HCl·H2O MW 578.94. 1H-NMR 
(DMSO-d6, ppm): δ 11.98 (br. s, 1H, NH+), 9.32 (s, 1H, N3-H), 7.70 (s, 
2H, Ar-2,5-H), 7.56-7.43 (m, 2H, Ar`-2,6-H), 7.28-7.15 (t def., 2H, Ar`-
3,5-H), 7.13-7.02 (d def., 2H, Ar-4,6-H), 6.73 (s, 1H, C=CH), 5.13 (s, 
2H, O-CH2), 4.04-2.96 (m, 12H, Pip, N3-CH2, N3-CH2-CH2-CH2, H3O+), 
2.79 (s, 3H, Pip-N-CH3), 2.01 (s, 2H, N3- CH2-CH2). LC/MS±: purity 
98.63 % tR = 4.03, (ESI) m/z [M+H]+ 452.42. Anal. calcd for 
C25H30FN5O2·3HCl·H2O: C, 51.86; H, 6.11; N, 12.10; found: C, 51.81; 
H, 5.86; N, 11.95. 
(Z)-2-Amino-5-(3-(4-chlorobenzyloxy)benzylidene)-3-(3-
morpholinopropyl)-3,5-dihydro-4H-imidazol-4-one hydrochloride (22) 
(Z)-5-(3-(4-Chlorobenzyloxy)benzylidene)-2-(methylthio)-3,5-dihydro-
4H-imidazol-4-one (42) (3 mmol, 1.08 g) and 3-morpholinopropan-1-
amine (3.5 mmol, 0.50 g) were used. Yellow solid. Yield  59 %; mp 185-
187 °C. C24H27ClN4O3·2HCl·2.5H2O MW 572.91. 1H-NMR (DMSO-d6, 
ppm): δ 11.44 (br. s, 1H, NH+), 9.61 (s, 1H, N3-H), 7.76-7.23 (m, 7H, 
Ar-2,5,6-H, Ar`-2,3,5,6-H), 7.09-6.90 (m, 1H, Ar-4-H), 6.75-6.51 (d def., 
1H, C=CH), 5.30-5.00 (m, 2H, O-CH2), 4.29-2.73 (m, 12H, Mor, N3-
CH2, N3-CH2-CH2-CH2, H3O+), 2.03 (s, 2H, 3- CH2-CH2). LC/MS±: 
purity 99.03 % tR = 5.10, (ESI) m/z [M+H]+ 455.31. Anal. calcd for 
C24H27ClN4O3·2HCl·2.5H2O: C, 50.31; H, 5.64; N, 9.78; found: C, 





4H-imidazol-4-one (42) (4 mmol, 1.30 g) and 3-(4-methylpiperazin-1-
yl)propan-1-amine (5.5 mmol, 0.87 g) were used. Cream solid. Yield 
87 %; mp 221-223 °C. C25H30ClN5O2·HCl·3H2O MW 558.93. 1H-NMR 
(DMSO-d6, ppm): δ 12.07 (s, 1H, NH+), 7.67-7.24 (m, 9H, C2-NH2, Ar-
2,5,6-H, Ar`-2,3,5,6-H), 7.09-6.94 (d def., 1H, Ar-4-H), 6.72 (s, 1H, 
C=CH), 5.24-5.07 (d def., 2H, O-CH2), 4.29-2.93 (m, 12H, Pip, N3-CH2, 
N3-CH2-CH2-CH2, H3O+), 2.78 (s, 3H, Pip-N-CH3), 2.22-1.92 (m, 2H, 
N3- CH2-CH2). LC/MS±: purity 97.54 % tR = 4.33, (ESI) m/z [M+H]+ 
470.40. Anal. calcd for C25H30ClN5O2·HCl·3H2O: C, 53.76; H, 6.69; N, 
12.54; found: C, 53.40; H, 6.82; N, 12.00. 
Biological assays 
Cell lines 
The mouse T-cell lymphoma L5178 cells (PAR) (ECACC Cat. No. 
87111908, coming  from FDA, Silver Spring, MD, USA) were 
transfected with pHa MDR1/A retrovirus. The ABCB1-expressing cell 
line L5178Y (MDR) was elected by the culture of the infected cells with 
colchicine. The parental mouse L5178 cells (PAR) and the subline 
L5178Y of human ABCB1-transfected mouse T-cell lymphoma (MDR) 
were cultured in McCoy’s 5A medium (Sigma-Aldrich, St Louis, MO, 
USA) supplemented with 10% heat-inactivated horse serum (Sigma-
Aldrich, St Louis, MO, USA), 200 mM L-glutamine (Sigma-Aldrich, St 
Louis, MO, USA), and a penicillin-streptomycin (Sigma-Aldrich, St 
Louis, MO, USA) mixture in concentrations of 100 U/L and 10 mg/L, 
respectively. The cell lines were incubated in a 5% CO2, 95% air 
atmosphere at 37 °C. 
Cytotoxicity assay 
The cytotoxicity of compounds was examined in PAR and MDR mouse 
T-lymphoma cell lines, using the MTT assay to calculate the IC50 values 
as described previously [24]. Mean IC50 values were obtained by best-
fitting the dose-dependent inhibition curves in GraphPadPrism5 
program (GraphPad Software version 5.00 for Windows, San Diego, 
CA, USA) from four parallel experiments for each cell line. 
Rhodamine 123 accumulation assay 
Compounds were tested for their ABCB1 efflux pump inhibiting activity 
using the rhodamine 123 accumulation assay according to the protocol 
described formerly [24]. The fluorescence activity ratio (FAR) was 










Studies in vitro on potential mechanism of ABCB1 modulation 
To determine influence on ATPase activity of 5-arylideneimidazolones, 
the luminescent Pgp‐Glo™ Assay System was used. It was purchased 
from Promega (Madison, WI, USA). Three repetitions of the assay was 
performed according to previously published data [28-30]. Compounds 
12, 20, and 22 (100 μM) were incubated with Pgp membranes for 40 
min at 37 °C. Other conditions were the same as described in our 
previous article [24]. Measurement of luminescence signal was done 
by a microplate reader EnSpire PerkinElmer (Waltham, MA, USA). 
GraphPad Prism 8.0.1 software was used for calculation of statistical 
significances. 
Pharmacophore modelling 
As the first step, 2D structures of the compounds 4, 5, 7-23 were 
converted into energy minimized 3D structures (OPLS3 force field [37]) 
using LigPrep (Schrödinger) [38] and the appropriate ionization states 
at pH = 7.0 ± 2.0 were assigned using Epik (Schrödinger) [39]. 
Subsequently, application of the Phase module (Schrödinger) [31] 
enabled to develop the pharmacophore model from the set of 
investigated, active/inactive compounds under the default settings 
(conformers generated during the search, not more than 50 conformers 
per structure, 10 hypotheses generated). The best hypothesis have 
mapped 100% of input actives and 40% of input inactives. 
Lipophilicity estimation using RP-TLC method 
The lipophilicity tests were carried out using the RP-TLC method. 
Mixtures of appropriate amounts of water and an organic modifier 
(methanol) ranging from 40 to 90% (v / v) in 5% steps were used as 
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F254 plates (14 x 10 cm) (Merck, Darmstadt, Germany). Methanol 
solutions of the analyzed compounds (in a volume of 10 µl) were 
applied to the plates in the form of 5 mm bands at intervals of 5 mm 
and 10 mm from the lower edge and sides of the plates using a Linomat 
V applicator (Camag, Basel, Switzerland). A vertical chromatography 
chamber (Sigma-Aldrich, St. Louis, USA) with dimensions of 20×10×18 
cm was saturated with the mobile phase for 20 min. The plates were 
developed to a height of 9.5 cm and then, after drying at room 
temperature, they were observed under ultraviolet light at 254 and/or 
366 nm (UV lamp, Camag, Basel, Switzerland). Each analysis was 
performed in triplicate and mean RF values (delay factor) were 
calculated. 
Based on the determined RF values, the RM parameters were 
calculated according to the formula:  
Then, linear correlations between the RM values for each of the tested 
substances and the concentration of the organic modifier in mobile 
phases were determined using the Soczewiński-Wachtmeister 
equation [40]: 
where C is the concentration of organic solvent (in%) in the mobile 
phase, and is the slope of the curve, and RM0 is the concentration of 
the organic modifier extrapolated to zero.  
Lipophilicity prediction in silico 
Computer-aided lipophilicity predictions were performed using the 
following bioinformatic tools: SwissADME (http://www.swissadme.ch/) 
[32], pkCSM (http://biosig.unimelb.edu.au/pkcsm/) [33], molinspiration 
(https://molinspiration.com/cgi-bin/properties) [34], and ALOGPS 
(http://www.vcclab.org/web/alogps/) [35,36]. Compounds 7–23 were 
drawn in basic forms. From obtained logP results, arithmetic mean and 
standard deviations were calculated. 
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Entry for the Table of Contents 
New 2-amine-5-arylideneimidazolones are promising chemical 
group for further development with proved selective cytotoxicity 
towards multidrug resistant cancer cells as well as ABCB1 
modulatory properties. The results from biological assays 
(MTT and rhodamine 123 accumulation) in combination with 
ABCB1 pharmacophore modeling were discussed in the 
structure-activity relationship section pointing out the lead 
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